The American Association of Clinical Endocrinologists’ 2022 Clinical Practice Guidelines for MASLD recommend GLP-1 receptor agonists (GLP-1 RAs) for individuals with type 2 diabetes (T2D) and biopsy-confirmed metabolic-associated steatohepatitis (MASH) or those at high risk of MASH to provide cardiovascular benefits [124,125]. Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.